Massive Changes in the Pharmaceutical Industry are a step closer to reality
Webinar presented by
John Shakow,
Partner, King & Spalding
John’s practice focuses on complex regulatory, commercial and litigation issues related to all aspects of drug pricing and price reporting. He counsels a diverse group of pharmaceutical and biotechnology manufacturer clients on all pricing-related rights and obligations under the Medicaid, Medicare, Federal Supply Schedule, 340B and TRICARE programs.
The AMP Rule is with OMB – What is the impact?
The OMB (Office of Management and Budget) has confirmed receipt and is reviewing the Final AMP Rule. When it passes, this ruling will transform government compliance requirements in the Pharmaceutical industry and significantly impact your business.
The OMB (Office of Management and Budget) has confirmed receipt and is reviewing the Final AMP Rule. When it passes, this ruling will transform government compliance requirements in the Pharmaceutical industry and significantly impact your business.
- What does the OMB submission mean to you?
- Are you prepared for the changes?
- How much time do you have to comply?
View this On-Demand webinar titled 'The AMP Rule is with OMB – What is the impact?' featuring John Shakow who will share his insights on what the OMB submission of the AMP ruling means to your business and walk through different scenarios.
Follow Us